ige receptors การใช้

• The high affinity IgE receptor is a key molecule involved in allergic reactions.
• This suggests that drugs to block the IgE receptor might block allergic response in humans.
• BTK plays a crucial role in B cell maturation as well as mast cell activation through the high-affinity IgE receptor.
• The classical mast cell markers include the high-affinity IgE receptor, CD117 ( c-Kit ), and CD203c ( for most of the mast cell populations ).
• The unique anti-IgE antibody was designed to target immunoglobulin E ( IgE ) and IgE-expressing B lymphocytes specifically, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils.
• Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor ( Fc?RI ) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
• Recent studies have shown that increased levels of soluble CD23 cause the recruitment of non-sensitised B-cells in the presentation of antigen peptides to allergen-specific B-cells, therefore increasing the production of allergen specific IgE . IgE, in turn, is known to upregulate the cellular expression of CD23 and Fc epsilon RI ( high-affinity IgE receptor ).
• Furthermore, although the peptide elements on IgE involved in binding to low affinity IgE receptor ( Fc?RII ) on many cell types are different from the peptide elements involved in binding to Fc?RI, omalizumab, by steric hindrance, also prevents binding of IgE to Fc?RII . The reduced binding of IgE to both Fc?RI and Fc?RII has profound effects on the attenuation of IgE-mediated allergic responses.
• Tanox started the " anti-IgE therapy " program and developed a prototype antibody candidate in 1987, and subsequently converted the mouse antibody candidate into a chimeric form and obtained crucial set of data on the antibody in 1988-89 . The Tanox'anti-IgE antibodies were designed to target free IgE in blood and IgE-expressing B lymphocytes for the purpose of intercepting the IgE-mediated pathway, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils or bound by the low-affinity IgE receptors on many cell types.
• Tanox started the " anti-IgE therapy " program and developed a prototype antibody candidate in 1987, and subsequently converted the mouse antibody candidate into a chimeric form and obtained crucial set of data on the antibody in 1988-89 . The Tanox'anti-IgE antibodies were designed to target free IgE in blood and IgE-expressing B lymphocytes for the purpose of intercepting the IgE-mediated pathway, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils or bound by the low-affinity IgE receptors on many cell types.